A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Sheehan, Sharon ^a   Harris, Stephanie A ^a   Satti, Iman ^a   Hokey, David A ^b   Dheenadhayalan, Veerabadran ^b   Stockdale, Lisa ^a   Manjaly Thomas, Zita Rose ^a   Minhinnick, Alice ^a   Wilkie, Morven ^a   Vermaak, Samantha ^a   Meyer, Joel ^a   O'Shea, Matthew K ^a   Pau, Maria Grazia ^c   Versteege, Isabella ^c   Douoguih, Macaya ^c   Hendriks, Jenny ^c   Sadoff, Jerald ^c   Landry, Bernard ^b   Moss, Paul ^d   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Aeras Global TB Vaccine Foundation   (United States)

^c Janssen Research and Development   (Netherlands)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AERAS 402 VACCINE; BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; CYTOKINE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BCG VACCINATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE REDNESS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; INSOMNIA; LOSS OF APPETITE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MALE; MIGRAINE; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PHASE 1 CLINICAL TRIAL; RHINORRHEA; RIGOR; SORE THROAT; TUBERCULOSIS; VOMITING; ADENOVIRIDAE; ADOLESCENT; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; SECONDARY IMMUNIZATION;

ADENOVIRIDAE; ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84951173385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141687     Document Type: Article

References (19)

1. WHO. Global tuberculosis report 2014. Available: http://www.who.int/tb/publications/global-report/en/. Accessed 19 November 2014.
2. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006; 367(9517):1173-80. doi: 10.1016/S0140-6736(06)68507-3 PMID: 16616560.
3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. PMID: 8309034.
4. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993; 22(6):1154-8. PMID: 8144299.
5. WHO. The Stop TB Strategy. Available: http://www.who.int/tb/strategy/stop-tb-strategy/en/.Accessed 19 November 2014.
6. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004; 10(11):1240-4. doi: 10.1038/nm1128 PMID: 15502839.
7. Hoft DF, Blazevic A, Stanley J, Landry B, Sizemore D, Kpamegan E, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine. 2012; 30(12):2098-108. doi: 10.1016/j.vaccine.2012.01.048 PMID: 22296955.
8. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb). 2004; 84(1-2):93-101. PMID: 14670350
9. Winslow GM, Cooper A, Reiley W, Chatterjee M, Woodland DL. Early T-cell responses in tuberculosis immunity. Immunol Rev. 2008; 225:284-99. doi: 10.1111/j.1600-065X.2008.00693.x PMID: 18837789; PubMed Central PMCID: PMCPMC3827678.
10. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012; 482(7383):89-93. doi: 10.1038/nature10766 PMID: 22217938; PubMed Central PMCID: PMC3271177.
11. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012; 7(2):e31208. doi: 10.1371/journal.pone.0031208 PMID: 22363582; PubMed Central PMCID: PMCPMC3283618.
12. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. American journal of respiratory and critical care medicine. 2010; 181(12):1407-17. doi: 10.1164/rccm.200910-1484OC PMID: 20167847; PubMed Central PMCID: PMC2894413.
13. Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine. 2013; 31(7):1026-33. doi: 10.1016/j.vaccine.2012.12.042 PMID: 23266342.
14. Graves AJ, Padilla MG, Hokey DA. OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2014; 85(7):576-9. doi: 10.1002/cyto.a.22478 PMID: 24866990; PubMed Central PMCID: PMC4231567.
15. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMID: 14605137; PubMed Central PMCID: PMC262545.
16. Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya MM, Whittaker M, et al. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. Human vaccines & immunotherapeutics. 2013; 9(1):50-62. doi: 10.4161/hv.22464 PMID: 23143773; PubMed Central PMCID: PMC3667946.
17. Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths K, Antrobus RD, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. The Lancet Infectious diseases. 2014; 14(10):939-46. doi: 10.1016/S1473-3099(14)70845-X PMID: 25151225; PubMed Central PMCID: PMC4178237.
18. Encinales L, Zuniga J, Granados-Montiel J, Yunis M, Granados J, Almeciga I, et al. Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Molecular immunology. 2010; 47(5):1066-73. doi: 10.1016/j.molimm.2009.11.005 PMID: 20004475; PubMed Central PMCID: PMC2815102.
19. Manivannan S, Rao NV, Ramanathan VD. Role of complement activation and antibody in the interaction between Mycobacterium tuberculosis and human macrophages. Indian J Exp Biol. 2012; 50(8):542-50. PMID: 23016491